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Global cancer sta�s�cs indicate that cancer is a leading cause of death worldwide, with 
an es�mated 14.1 million new cases and 8.2 million deaths in 2012 [1, 2]. By 2030, the 
global cancer burden is expected to grow to 21.7 million new cancer cases and 13 million 
cancer deaths due to popula�on growth and aging. Yet, this might be considerably higher 
due to the adop�on of lifestyles that are known to increase cancer risk, including smok-
ing, poor dietary habits and lack of physical ac�vity [1, 2]. 
 Up �ll now, treatment approaches for individual cancer pa�ents have been based on 
popula�on-based evidence, mostly from general clinical prac�ces or clinical trials. It has 
become apparent that tumors and pa�ents might be more heterogeneous than previ-
ously assumed, which calls for moving ahead from a popula�on-based approach to pre-
cision oncology [3]. With an ever-increasing number of treatment op�ons are becoming 
available, all poten�ally relevant available factors should therefore be taken into account 
in order to select the most op�mal treatment [4-6]. 
 Medical imaging is the cornerstone for the management of pa�ents with all kinds of 
diseases, especially for cancer, and is used for diagnosis, treatment planning, monitoring 
treatment response and image-guided interven�ons. However, besides rela�vely few 
rou�ne quan�ta�ve metrics, such as RECIST [7], images are mostly used in a qualita�ve 
manner in current clinical prac�ce. 
 
Figure 1 – Schema�c example of the development of a clinical decision support system (CDSS) with radiomics.
The ﬁrst step for radiomics is the acquisi�on and segmenta�on (ROI: Region of Interest) of medical images.
From this image data, radiomic features are extracted and stored in a database. For each pa�ent, data from
other relevant sources of informa�on, such as clinical and molecular data, are collected and added to a data-
base. These data sources are subsequently merged and this combined database is then analyzed to develop







































































radiomics,  which  is  illustrated  by  the  development  of  a  clinically  relevant  prognostic 
model. This study investigates an association of post‐radiochemotherapy PET radiomics 
with local tumor control in head and neck squamous cell carcinoma, using two different 
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Radiomics  is  een  proces  waarbij  (standaard)  medische  beelden  worden  verwerkt  tot 
kwantitatieve data, met als doel deze data–bijvoorbeeld in de vorm van diagnostische, 

























































acquisi�e- en reconstruc�e instellingen om subjec�eve vereisten van de expert aan me-
dische beelden te faciliteren.  
 Een recente studie van Mackin et al. [5] hee� aangetoond dat radiomics textuur pa-
rameters die geëxtraheerd zijn uit CT-beelden van een fantoom kunnen variëren per CT-
scanner. Deze varia�es kunnen zorgen voor een bias die de werkelijke onderliggende (bi-
ologische) karakteris�eken maskeert. Er zijn verschillende ini�a�even om beeldacquisi�e 
en reconstruc�e te standaardiseren, voor zowel PET (NEDPAS [6], EANM [7]), CT (ICRU 
[8]) en MRI (AAPM [9]). Daarnaast zijn er interna�onale organisa�es of consor�a die 
beeldacquisi�e verbeteren om het gebruik van kwan�ta�eve beeldbiomarkers mogelijk 
te maken, zoals het Quan�ta�ve Imaging Network (QIN) [10] en het QuIC-ConCePT pro-
ject (www.quick-concept.eu) van het Innova�ve Medicine Ini�ative Joint Undertaking 
(IMI JU).  
 Naast inter-scanner variabiliteit en het gebruik van verschillende acquisi�e en recon-
struc�e parameters kan ook de veranderende anatomie van de patiënt de kwan�ﬁca�e 




Figuur 1 – Overzicht van de stappen om tot een klinisch keuzehulp systeem met radiomics te komen. De eerste
stap voor radiomics is de acquisi�e en segmenta�e van medische beelden. Uit deze beelddata worden vervol-
gens radiomics beeldeigenschappen geëxtraheerd en in een database opgeslagen. Van elke pa�ënt wordt te-
vens klinische en moleculaire data in een database verzameld. Deze bronnen van data worden samengevoegd
en deze gecombineerde database wordt vervolgens geanalyseerd om diagnos�sche, prognos�sche en predic-
�eve modellen te ontwikkelen. 





1 0 0 1 1 0 1 1 0 1 
0 1 0 1 0 1 1 0 0 0 
1 1 0 1 0 1 0 0 0 1 
0 1 0 1 0 1 0 1 0 1
1 0 0 1 1 0 1 1 0 1 
0 1 0 1 0 1 1 0 0 0 
1 1 0 1 0 1 0 0 0 1 
0 1 0 1 0 1 0 1 0 1






































histogram  van  intensiteitswaarden.  De  tweede  groep  beschrijft  de  drie  dimensionale 

















































































ontwikkeling  worden  beeldeigenschappen  gegroepeerd  op  basis  van  vooraf  gedefini‐
eerde informatie en klinische context. Voor beide methoden is het van belang een goed 
gedefinieerde  uitkomst  te  hebben  (bijv.,  overlevingstijd  of  progressievrije  overleving). 
Idealiter  wordt  radiomics  gecombineerd  met  niet‐radiomics  data,  inclusief  reeds  be‐
kende  klinische  voorspellers. Hierdoor  kan de  toegevoegde waarde  van  radiomics  ge‐
toetst worden en kunnen tevens nieuwe modellen ontwikkeld worden die biologische, 

















(recente)  overzichtspublicaties  [24‐31].  Er  zijn  radiomics  studies  uitgevoerd  voor  een 
groot aantal  indicaties, zoals  long‐, hoofd‐hals‐, prostaat‐, rectum‐, slokdarmkanker en 










studie  samenvat  is  te  vinden onder  de  volgende  link:  https://youtu.be/Tq980GEVP0Y. 
Hoewel  het  eerdergenoemde  radiomics‐profiel  zowel  in  long  als  in  hoofd‐halskanker 
prognostisch is, laat een studie door Parmar et al. [34] zien dat op CT gebaseerde radio‐
mics  beeldkenmerken op  specifieke wijze  clusteren  voor  beide  kankertypes, wat  aan‐
toont dat er zowel generieke als ziekte specifieke radiomics informatie te kwantificeren 
is. 











































































en lokale dataservers. Een anima�e die dit concept toelicht is te vinden onder de vol-
gende link: h�ps://youtu.be/ZDJFOxpwqEA. 
 We voorzien dat radiomics in de nabije toekomst een steeds belangrijkere rol gaat 
spelen. Beslishulpen en voorspellende modellen zullen steeds vaker de kennis van radio-
mics parameters gebruiken, die geëxtraheerd zijn uit ‘rapid learning healthcare’ netwer-
ken. Daarnaast zal radiomics ook zijn weg vinden naar de radiologie, waar de beoordeling 
van beelden vooral gebaseerd is op een subjec�eve interpreta�e en intrinsieke kennis. 
Radiomics kan een objec�eve, kwan�ta�eve en tevens probabilis�sche beoordeling bie-
den, i.e. “kwan�ta�eve radiologie” (een voorbeeld hiervan is screenen op longkanker 
[53]). Om deze visie te laten slagen is het echter cruciaal dat het belang van standaardi-
sa�e, automa�sering en data-uitwisseling wordt erkend en dat dit, met betrokkenheid 
van artsen, wordt geïntegreerd in de standaard klinische prak�jk. 
AANWIJZINGEN VOOR DE PRAKTIJK 
 Radiomics is een proces waarbij standaard medische beelden (e.g. CT, PET, MR) 
worden verwerkt tot grote hoeveelheden kwan�ta�eve data. 
 Radiomics hee� de poten�e om, door toevoegen van informa�e u it standaard 
beeldvorming, klinische beslishulpsystemen te verbeteren 
 Implementa�e van radiomics in de klinische prak�jk is niet zonder uitdagingen. 
Met name standaardisa�e is van groot belang. 
 
 
Figuur 3 – Schema�sch overzicht van een keuzehulp systeem dat gebruikt maakt van het -radiomics principe.
Op basis van het radiomics-proﬁel dat gemaakt is van de diagnos�sche scan, kunnen veranderingen gedurende
de behandeling worden gemonitord. Bij signiﬁcante afwijkingen �jdens de radiotherapie kan er vervolgens be-
sloten worden een geüpdatet bestralingsplan te maken op basis van een nieuwe (PET-)CT-scan. 























































































































































































































































































measurements  and  features  describing  histogram  of  voxel  intensity  values  contained 
within the VOI. 
STABILITY OF FDG-PET RADIOMICS FEATURES 
31 
 
Figure 1 – Schema�c of the workﬂow applied in our study: (A) Acquisition of PET images (fused CT for illustra�ve
purposes), followed by tumour delinea�on; (B) Extrac�on of Radiomics features from the deﬁned volume of
interest; (C) Test-retest and inter-observer stability analysis. 
 
 
Figure 2 – (A and B) Representa�ve images of repeated imaging of a patient from the test-retest cohort, with
the 50% SUVmax tumour delinea�on shown outlined in green, for respec�vely the ﬁrst and second baseline PET
scan. (C) Representa�ve image of a pa�ent from the inter-observer cohort, where the lesion area is outlined
with the green square (fused CT for illustra�ve purposes); (D) Enlargement of the lesion area with in diﬀerent
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server  COV  values,  we  normalized  them  to  a  percentage  of  the  mean  feature  value 
(COV%mean) as well as the range of feature values (2.5 – 97.5 percentile; COV%range) over all 






































cients.  Plotted  diagonal  illustrates  perfect  correlation.  (A)  First  order  statistics  (ρS=0.877,  p<<0.001ρୱ ൌ
0.877, p ≪ 0.001).  (B)  Intensity volume histogram  features  (ρS=0.572, p<<0.001ρୱ ൌ 0.572, p ൌ 0.001).  (C)
Geometric features (ρS=0.663, p<<0.001ρୱ ൌ 0.663, p ൌ 0.086). (D) Textural features (ρS=0.719, p<<0.001ρୱ ൌ






















































































Stability class  N ICC COV%mean (%) COV%range (%) 
First order statistics
High stability  13  0.81 ‐ 0.96 (0.92)  17.27 ‐ 86.29 (23.45)  12.22 ‐ 35.36 (14.67) 
Medium stability  0  ‐  ‐  ‐ 
Low stability  2  0.27 ‐ 0.28 (0.27)  57.29 ‐ 110.48 (83.89)  55.61 ‐ 60.58 (58.09) 
IVH features 
High stability  18  0.80 ‐ 0.94 (0.86)  17.09 ‐ 44.07 (29.19)  3.39 ‐ 23.78 (14.82) 
Medium stability  3  0.61 ‐ 0.78 (0.77)  37.26 ‐ 105.65 (50.40)  6.03 ‐ 28.04 (20.33) 
Low stability  8  0.00 ‐ 0.48 (0.27)  7.68 ‐ 99.25 (46.30)  46.82 ‐ 68.00 (60.54) 
Geometric features 
High stability  8  0.81 ‐ 0.88 (0.83)  12.25 ‐ 37.61 (29.53)  3.80 ‐ 31.58 (18.79) 
Medium stability  0  ‐  ‐  ‐ 
Low stability  0  ‐  ‐  ‐ 
Textural features 
High stability  29  0.81 ‐ 0.93 (0.89)  2.76 ‐ 166.45 (36.90)  5.94 ‐ 36.42 (19.25) 
Medium stability  14  0.54 ‐ 0.79 (0.64)  3.57 ‐ 465.37 (75.93)  4.32 ‐ 54.56 (33.96) 
Low stability  1  0.35  84.19  53.59 
 
 
Table 2 – Results for the  inter‐observer analysis, showing  ICC, COV%mean and COV%range  ranges, as well as the 
number of features per feature group and per class, defined as high (ICC≥0.8), medium (0.8>ICC≥0.5), or low 
(ICC<0.5) stability. Median values of ICC, COV%mean and COV%range ranges are shown within brackets. 
Stability class  N  ICC  COV%mean (%)  COV%range (%) 
First order statistics 
High stability  14  0.87 ‐ 1.00 (0.98)  2.07 ‐ 58.17 (15.25)  1.20 ‐ 22.75 (7.39) 
Medium stability  1  0.79  65.81  41.21 
Low stability  0  ‐  ‐  ‐ 
IVH features 
High stability  34  0.82 ‐ 1.00 (0.97)  5.60 ‐ 131.45 (28.57)  1.23 ‐ 52.15 (10.70) 
Medium stability  5  0.63 ‐ 0.77 (0.72)  4.53 ‐ 39.04 (21.74)  38.72 ‐ 57.65 (51.14) 
Low stability  0  ‐  ‐  ‐ 
Geometric features 
High stability  8  0.80 ‐ 0.98 (0.97)  11.63 ‐ 48.47 (26.79)  9.60 ‐ 31.31 (19.20) 
Medium stability  0  ‐  ‐  ‐ 
Low stability  0  ‐  ‐  ‐ 
Textural features 
High stability  39  0.80 ‐ 0.99 (0.95)  1.20 ‐ 257.20 (28.61)  5.34 ‐ 40.03 (13.19) 
Medium stability  3  0.50 ‐ 0.77 (0.75)  44.46 ‐ 128.87 (104.07)  12.38 ‐ 51.25 (30.16) 




Increased  investigation of quantitative  imaging  features  to monitor  response  to  treat‐
ment, treatment outcome or as potential imaging biomarkers, raised the requisite to val‐































































that  features more  stable  in  repeated  PET  imaging were  in  general  also more  robust 












































































































We  focused  on  the  implications  of  the  manner  in  which  this  discretization  is  imple‐
mented.  Two methods were  evaluated:  (1)  RD,  dividing  the  SUV  range  into D  equally 











































































Methodology  to determine tumor texture
Interchangeable absolute SUV 
measurements








formed on a Biograph 40 PET/CT scanner  (Siemens Medical Solutions)  twice:  (1) after 
induction chemotherapy but before radiotherapy and (2) during the second week of ra‐



















  ܫ஻ሺݔሻ ൌ ඄ܫሺݔሻܤ ඈ െ min ൬඄
ܫሺݔሻ
ܤ ඈ൰ ൅ 1  (1) 
Where term ሾminሺڿܫሺݔሻ ܤ⁄ ۀሻ ൅ 1ሿ ensures that the bin count starts at 1. We us the short‐
hand notation RB for this resampling method. Resampling SUVs into D bins was performed 
using: 
  ܫ஽ሺݔሻ ൌ ൞
1 ܫሺݔሻ ൌ ܷܵ ௠ܸ௜௡
ቜܦൈ ܫሺݔሻ െ ܷܵ ௠ܸ௜௡ܷܵ ௠ܸ௔௫ െ ܷܵ ௠ܸ௜௡ቝ otherwise
  (2) 






Textural features describing the spa�al distribu�on of voxel intensi�es were calculated 
from gray-level co-occurrence (GLCM) [38], gray-level run-length (GLRLM) [39] and gray-
level size-zone texture matrices (GLSZM) [22]. Texture matrices were determined by con-
sidering 26 connected voxels (i.e. voxels were considered to be neighbors in all 13 direc-
�ons in three dimensions) at a distance of 1 voxel. Features derived from GLCM and 
GLRLM were calculated by averaging their value over all 13 direc�ons. In total, 44 textural 
features (22 GLCM, 11 GLRLM and 11 GLSZM) were calculated. Changes in feature values 
between the pre-treatment and during treatment imaging �me points were described as 
delta features, deﬁned as: 
  (3) 
 
Figure 2 – Left column: Representa�ve images of sequen�al imaging for one pa�ent, showing pre-treatment
imaging (a) and imaging during the second week of radiotherapy (b). The tumor delinea�on is outlined in green.
Both images are displayed with the same window/level se�ngs. Right column: Histograms of the pre-treatment
and during treatment images, resampled with a ﬁxed bin size (i.e. intensity resolu�on) (c) or a predeﬁned num-
ber of bins (d). In (d), one can appreciate the diﬀerence in resul�ng intensity resolu�on when resampling with
a ﬁxed number of bins. Pre-treatment and during treatment intensity resolu�ons were 0.6 and 0.37 [SUV], re-
spec�vely. 
a
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  ܫܥܥ ൌ ܤܯܵ െܹܯܵܤܯܵ ൅ܹܯܵ  (4) 
Where BMS and WMS are the between‐subjects and within‐subjects mean squares, re‐























intra‐lesional  intensity resolution, which  is directly proportional  to the SUV range. The 
ratio of the largest with the smallest observed intensity resolution was 1254% for pre‐
treatment imaging and 1038% for during treatment imaging. Absolute percentage differ‐































ings for both discretization methods (i.e. all pairwise ߩ஻஻ ൐ 0.9 and all pairwise ߩ஽஽ ൐
0.9), meaning that patient rankings were nearly not affected by changes in intensity res‐





































We compared  tumor  texture analysis based on SUV discretization using either a  fixed 
number of bins (RD) or a fixed bin size in units SUV (RB), in the context of clinical treatment 















































































cretization method or discretization value used  (Figure 4‐5). This  suggests  that  results 
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gle‐institution  settings  and  consequently,  the  importance of workflow  standardization 
has been indicated [5, 6]. 
  Radiomics analysis requires several image pre‐processing steps such as region of in‐




which are often  in‐house developed. Although  the  implementations are based on  the 
same mathematical definitions, it is likely that they will produce different results due to 
differences in implementation of algorithms as well as pre‐processing [11].  

















ent models were  trained using  two  independent  radiomics  implementations and their 
performance was validated  in a separate dataset. Subsequently,  the  reproducibility of 














































      Training cohort  Validation cohort 
    Total number of patients  128  50 
    Median  follow‐up 
(months) 
46 (3‐156)  16 (3‐28) 
    Number  of  local  recur‐
rences 
38 (30%)  13 (26%) 
Tumor stage    T1/T2  43 (34%)  6 (12%) 
  T3/T4  85 (66%)  44 (88%) 
HPV status    Positive  31 (24%)  22 (44%) 
  Negative  36 (28%)  28 (66%) 
  Unknown  61 (48%)  0 
Tumor site    Oropharynx  91 (71%)  29 (58%) 
  Hypopharynx  22 (17%)  7 (14%) 
  Larynx  11 (9%)  7 (14%) 
  Oral cavity  4 (3%)  7 (14%) 
Treatment    Radiotherapy  on average 70 Gy  
(68 – 72 Gy) 
70 Gy 
    Chemotherapy  Cisplatin  (40 








as  in  training  cohort) 

























components was adjusted  to  represent 95% of data variance. Next,  for each principal 
component one  feature was  selected  to  represent  it.  To  that end we determined  the 




































































> threshold validationModel validation in
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  Each  trained model, based on  the  features calculated  in one  implementation, was 
later evaluated by calculating its respective features with the other independent imple‐
mentation (Figure 1). The regression coefficients of the Cox model and the stratification 
































































showed  that  the general discriminative power of  the models was not affected by  the 
change of the implementation. On the patient level, a strong correlation was observed 
















MAASTRO features  training  0.76  0.75 validation  0.73  0.73 
USZ features  training  0.75  0.74 validation  0.71  0.72 
Calibration slope 
MAASTRO features    1.20 (0.39 – 2.02)*  1.04 (0.27 – 1.95)* 
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other centers as  the  lack of calibration between different PET scanners can affect  the 
performance of  the models  [19]. Additionally, we have defined our  region on  interest 
based on the pre‐treatment PET images and propagated it to the post‐treatment scan. 
















































































































ical definition of  radiomic  features. Additionally,  the  image pre‐processing  (image and 
region of interest resizing) was performed independent of the radiomics implementation 
and the same bin size was used for  image discretization [20]. Nevertheless, a relevant 
variability  in  radiomic  features value was observed, mostly  for  the  shape and wavelet 
features.  It was most  probably  caused by  differences  in mask  extraction  and wavelet 














































program  (ARTFORCE  ‐  n°  257144,  REQUITE  ‐  n°  601826),  SME  Phase  2  (EU  proposal 
673780 – RAIL), EUROSTARS (DART), the European Program H2020‐2015‐17 (BD2Decide 
































































Figure 1S – The reproducibly of radiomics features between the implementa�ons. a) Histogram of reproducible
radiomic features. The intensity and texture features showed a high level of agreement between the imple-
menta�ons. The irreproducibility of shape and wavelet features was caused by diﬀerences in mask extrac�on
and wavelet maps normaliza�on. b) Intraclass correla�on coeﬀicient for diﬀerent features, H – high-pass ﬁlet,
L – low-pass ﬁlter. The features where high-pass ﬁlter was applied more than once were the least reproducible.
The diﬀerence between the implementa�on in wavelet maps normaliza�on did not have a big inﬂuence on the
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ment. By assessing  the characteristics of human  tissue non‐invasively,  imaging  is often 
used in clinical practice for oncologic diagnosis and treatment guidance [1‐3]. A key goal 












  The most widely used  imaging modality  in oncology  is x‐ray computed  tomography 
(CT), which  assesses  tissue  density.  Indeed,  CT  images  of  lung  cancer  tumours  exhibit 
strong contrast reflecting differences in the intensity of a tumour on the image, intra tu‐
mour  texture,  and  tumour  shape  (Figure 1a).  However,  in  clinical  practice,  tumour  re‐
sponse to therapy is only measured using 1 or 2 dimensional descriptors of tumour size 





















and head-and-neck cancer pa�ents, and are associated with the underlying gene-expres-
sion pa�erns. These results suggest that radiomics decodes a general prognos�c pheno-
type exis�ng in mul�ple cancer types. Radiomics can have a large clinical impact, as imag-
ing is used in rou�ne prac�ce worldwide, providing a method that can quan�fy and mon-




Figure 1 – Extracting radiomics data from images. (a) Tumours are diﬀerent. Example computed tomography
(CT) images of lung cancer pa�ents. CT images with tumour contours le�, three-dimensional visualiza�ons right.
Please note strong phenotypic diﬀerences that can be captured with rou�ne CT imaging, such as intratumour
heterogeneity and tumour shape. (b) Strategy for extrac�ng radiomics data from images. (I) Experienced phy-
sicians contour the tumour areas on all CT slices. (II) Features are extracted from within the deﬁned tumour
contours on the CT images, quantifying tumour intensity, shape, texture and wavelet texture. (III) For the anal-





































Unsupervised  clustering  revealed  clusters of patients with  similar  radiomic expression 
patterns (Figure 3). We compared the three main clusters of patients with clinical param‐
eters (Figure 3b), and found significant association with primary tumour stage (T‐stage; 
݌	 ൏ 1ൈ10ିଶ଴, ߯ଶ test) and overall stage (݌ ൌ 3.4ൈ10ିଷ, ߯ଶ test), wherein cluster I was 
associated with lower stages. N‐stage (lymph node) and M‐stage (metastasis), however, 
showed no correspondence with the radiomic expression patterns (݌ ൌ 0.46, and ݌ ൌ
0.73 respectively, ߯ଶ test). 






































Feature selection based 


















at the representa�on of the feature groups (Figure 3c), there was no correspondence 
between the feature group and radiomic expression pa�erns. 
 
 
Figure 3 – Radiomics heat map. (a) Unsupervised clustering of lung cancer pa�ents (Lung1 set, n=422) on the y-
axis and radiomic feature expression (n=440) on the x-axis, revealed clusters of pa�ents with similar radiomic
expression pa�erns. (b) Clinical pa�ent parameters for showing signiﬁcant associa�on of the radiomic expres-
sion pa�erns with primary tumour stage (T-stage;  test), overall stage (
test), and histology (  test). (c) Correspondence of radiomic feature groups with the clustered
expression pa�erns. 
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  The  resulting  radiomic  signature  consisted of  (I)  ‘Statistics Energy’  (Supplementary 
Methods Feature 1) describing the overall density of the tumour volume, (II) ‘Shape Com‐






The performance of  the  four  feature radiomic signature was validated  in  the datasets 
Lung2, H&N1, and H&N2 (Figure 2) using the concordance index (CI), which is a generali‐
zation of the area under the ROC‐curve [12]. The radiomic signature had good perfor‐
mance on the Lung2 data (CI ൌ 0.65, ݌ ൌ 	2.91ൈ10ି଴ଽ, Wilcoxon test), and a high per‐
formance  in  H&N1  (CI ൌ 0.69, ݌ ൌ 	7.99ൈ10ି଴଻,  Wilcoxon  test)  and  H&N2  (CI ൌ
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Figure 4 – Prognostic performance and gene-expression association of the radiomics signature. (a) Radiomic sig-
nature performance. Kaplan–Meier curves demonstra�ng performance of the radiomic signature on the lung
cancer data sets (le�) and the head-and-neck cancer data sets (right). The signature was built on the Lung1 data
(n=422). The signature had a good performance in the Lung2 (CI , Wilcoxon test,
n=225), and a high performance in H&N1 (CI , Wilcoxon test, n=136) and H&N2 (CI
, Wilcoxon test, n=95) valida�on data sets. (b) Associa�on of radiomic signature features
and gene expression using gene-set enrichment analysis (GSEA) in the Lung3 data set (n=89). Gene sets that
have been signiﬁcantly enriched (FDR=20%) for at least one of the four radiomic features are indicated with an
asterisk. The corresponding normalized enrichment scores (NES), GSEA’s primary sta�s�c, for all radiomic sig-
nature features is displayed in a heat map, where light blue means low and dark blue means high NES. 












































* * * * * * * * * * * * * *
* * * * * *
* * * * * * * * *


























































































































































































































































































































































RLGL grey level nonuniformity














ing  that  radiomic  features  probe different  biologic mechanisms.  It  is  noteworthy  that 


























































































of  radiomics  with  clinical  factors,  prognosis,  and  gene‐expression  levels,  using  large 
amounts of features and with external and independent validation cohorts of patients. 
The most important message in our manuscript is that there is prognostic and biologic 














  Due to the  large availability of non‐invasive  imaging performed routinely  in a  large 
number of  cancer patients,  and  the automated  feature algorithms,  the  results of  this 
work could stimulate further research of image‐based quantitative features. Also, we pre‐
sented evidence  that  the defined  radiomic  feature‐metrics are platform  independent, 
though this should be studied further, and can potentially be applied to other image mo‐
























presented  in Figure 2. All  research was carried out  in accordance with Dutch  law. The 
Institutional Review Boards of each of  the participating centres approved  the  studies: 
Lung1, Lung3, H&N1 (Maastricht University Medical Center (MUMC+), Maastricht, The 
Netherlands), Lung2 (Radboud University Medical Center (RUMC), Nijmegen, The Neth‐
erlands)  and  H&N2  (VU  University Medical  Center  (VUMC),  Amsterdam,  The  Nether‐
lands).  The  Multiple  delineation  data  set  is  publicly  available  (downloaded  from: 
www.cancerdata.org). This study was conducted according to national laws and guide‐




















 The H&N1  data  set  consists  of  136  head‐and‐neck  squamous  cell  carcinoma 
















NSCLC patients,  and  the  Lung3 data  set  consisting  of  CT  images  and  gene‐expression 











distinct groups. Patients were  included  in  the analysis with the following criteria: con‐




























































high  to  low agreement. Each of  these gene ranks were used  to perform a pre‐ranked 








































































































































We  identified 267  (49%) patients without and 275  (51%) with visible CT artifacts. The 
calibration slope (ߚ) on the PI  in a Cox proportional hazards model was 1.27  (ܪ଴:	ߚ ൌ
1, ݌ ൌ 0.152) in the PMH1 (n = 542), 0.855 (ܪ଴:	ߚ ൌ 1, ݌ ൌ 0.524) in the PMH2 (n = 267) 
and 1.99  (ܪ଴:	ߚ ൌ 1, ݌ ൌ 0.002)  in  the  PMH3  (n  =  275)  cohort. Harrell’s  c‐index was 












Accounting  for  approximately  half  a million  cases  annually worldwide,  head  and neck 













imaging  is  used  routinely  throughout  the  course  of  treatment  and  therefore  there  is 
ready access to this useful information. 
  Radiomics is a high‐throughput approach to translate medical images into mineable 
data by extracting a  large number of quantitative  features describing  tumor  intensity, 
shape, and texture [12‐14]. The hypothesis being that a comprehensive and robust [15‐
19] quantification of imaging phenotypes provides complementary and clinically relevant 





was derived  from non‐small  cell  lung cancer  (NSCLC) patients and  independently  vali‐
dated to be not only prognostic in NSCLC, but as well in two HNSCC patient cohorts, of 
which all patients were treated in the Netherlands. In this study, we aim to further vali‐























from the GTV:  (1)  “First order  statistics: Energy”, describing  the overall density of  the 
tumor  volume;  (2)  “Shape:  Compactness”,  quantifying  the  compactness  of  the  tumor 
volume relative  to  that of a sphere  (i.e.  the most compact shape);  (3) “Gray  level  run 



















































was significant (߯ସଶ ൌ 21.87, p ൌ 2.13݁ െ 4). Harrell’s c‐index for the PI was found to be 




(ܵܧ	 ൌ 	0.236) and not significantly different from 1 (p ൌ 0.524). In the model with the 
PI offset, the joint test of all individual feature coefficients was significant (߯ସଶ ൌ 12.31, 
p ൌ 0.015). Harrell’s c‐index for the PI was 0.634 (p ൌ 2.7݁ െ 6) and a significant differ‐
ence between survival curves was observed (p ൌ 4.89݁ െ 5)  in  this subset of patients 
(Figure 2a). 
  Considering patients with visible CT artifacts (PMH3; n = 275), the calibration slope on 
the PI was 1.99 (ܵܧ ൌ 0.273), which was significantly different from 1 (p ൌ 0.002). The 
joint test of all predictors was significant (߯ସଶ ൌ 16.81, p ൌ 0.002) in the model with the 







dation cohort for all patients (log‐rank test p ൌ 1.93݁ െ 5) and for the subset of patients without (log‐rank test
p ൌ 4.89݁ െ 5) and with (log‐rank test p ൌ 0.004) visible CT artifacts within the GTV. (b) Survival curves for the
MAASTRO “H&N1” (log‐rank test p ൌ 8.48݁ െ 05) and VUmc “H&N2” (log‐rank test p ൌ 0.030) cohorts as re‐
ported by Aerts et al. 

























* ******** ** *** *
****












1.0 * * *** * ** * **** ** ************************** ********************** ****** ******** * * *
*
*
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**** * ****** ********* ************* ******** ** **** * *
PMH: all (n=542)


















First order statistics  Energy  2.42݁ െ 11 
Shape  Compactness െ5.38݁ െ 03	
Gray level run length Gray level non‐uniformity െ1.47݁ െ 04	

















Gender           
Male  79.9 82.0 77.8 81.5 65.3 
Female  20.1 18.0 22.2 18.5 34.7 
Primary tumor site 
Oropharynx  100.0  100.0  100.0  64.0  100.0 
Larynx  0  0  0  36.0  0 
T‐category           
T1  12.5 13.9 11.3 25.9 10.5 
T2  31.9 32.6 31.3 23.0 32.6 
T3  33.4 33.3 33.5 17.8 35.8 
T4  22.1  20.2  24.0  33.3  21.1 
N‐category           
N0  17.3  16.1  18.5  45.2  44.2 
N1  10.3  10.1  10.5  11.9  11.6 
N2  65.7 65.5 65.8 40.7 42.1 
N3  6.6 8.2 5.1 2.2 2.1 
Overall stage 
Stage I  12.5  13.9  11.3  18.5  8.4 
Stage II  31.9  32.6  31.3  8.1  18.9 
Stage III  33.4  33.3  33.5  17.0  18.9 
Stage IVA  15.7 13.1 18.2 54.3 45.3 
Stage IVB  6.5 7.1 5.8 2.2 7.4 
Stage IVC  0 0 0 0 1.1 
HPV/p16 status  p16  p16  p16  HPV#  HPV 
Positive  56.3  49.4  62.9  28.4  18.9 
Negative  24.0  30.3  17.8  71.6  81.1 
Unknown  19.7  20.2  19.3  0  0 
Treatment 
Radiotherapy  49.1 55.4 42.9 74.1 58.9 













before feature calculation. Even though  it  is known that scanner parameters  (i.e. slice 
thickness or reconstruction kernels), which differ across and within patient cohorts, affect 
textural features computed from CT images [30], Aerts et al. [27] showed translational 







et al., for both the MAASTRO “H&N1” (p ൌ 8.48݁ െ 05) and VUmc “H&N2” (p ൌ 0.030) 
cohorts and a  side‐by‐side comparison of  survival  curves  is depicted  in Figure 2. Even 
though our study endorses translational potential of the radiomic signature, we believe 
that standardization of  imaging protocols should be pursued to eliminate variability  in 

































screening  for  instance provides complementary  information  to  the  radiomic  signature 
[27]. Deriving a novel and disease specific signature for head and neck cancer [34], com‐




a  large  OPSCC  cohort.  Overall,  the  signature  validated  well  using  all  CT  images  as‐is, 
demonstrating a good model fit and preservation of discrimination. Our results showed 














































and  branched  evolution  revealed  by  multiregion  sequencing.  The  New  England  journal  of  medicine 
2012;366: 883‐892. 
[11]  Panth KM, Leijenaar RT, Carvalho S, Lieuwes NG, Yaromina A, Dubois L, et al. Is there a causal relationship 





























































































































  Radiomics  is a rapidly emerging field,  introduced in 2012, which concerns with the 
high‐throughput mining of large amounts of quantitative features, derived from (stand‐
ard‐of‐care)  medical  imaging,  for  knowledge  extraction  [6‐8]  (also  see:  www.radi‐





























terpolation  [17].  A  total  of  902  radiomic  features  were  calculated,  divided  into  five 
groups: tumor intensity, shape, texture, Wavelet and Laplacian of Gaussian. All features 
were extracted using in‐house developed software, using Matlab 2014a (MathWorks, Na‐































































































































HPV (p16) status             
Positive  303 (71%)  34 (22%)  56 (56%)  33 (35%)  344 (55%)  82 (55%) 
Negative  124 (29%)  124 (78%)  44 (44%)  60 (65%)  284 (45%)  68 (45%) 
CT artifacts             
Yes  219 (51%)  69 (44%)  57 (57%)  26 (28%)  300 (48%)  71 (47%) 
No  208 (49%)  89 (56%)  43 (43%)  67 (72%)  328 (52%)  79 (53%) 
Overall survival             
Median follow up (months)  71.6  74  44.5  51.8  69.4  65.1 
Cohort             
PMH  ‐  ‐  ‐  ‐  343 (55%)  84 (56%) 
VUmc  ‐  ‐  ‐  ‐  128 (20%)  30 (20%) 
USZ  ‐  ‐  ‐  ‐  82 (13%)  18 (12%) 
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dental  fillings or other high atomic number material  implants, which result  in  imaging 
artifacts [30]. An existing radiomic signature for overall survival [7] has previously been 













































TNM and overall  stage,  as  these  are  related  to other HNSCC  [35]. HPV has  also been 
shown to affect the morphology of affected lymph nodes [36]. Including radiomics of in‐
volved lymph nodes could potentially provide additional value in predicting HPV status. 










pean  Program  H2020‐2015‐17  (BD2Decide  ‐  PHC30‐689715  and  ImmunoSABR  ‐  n° 







































































































Cancer Center  (PMH) between 2005 and 2010 were  included  in  this study. Treatment 
consisted of radiotherapy or concurrent chemoradiotherapy, with standard fractionated 
IMRT up to 70Gy. All patients underwent pre‐treatment CT imaging of the head and neck 









Contrast  enhanced  CT  images were  acquired  according  to  the  institutional  treatment 
planning protocol (tube voltage 120kV or 140kV; median tube current 214 mAs (60‐450 
mAs); median slice thickness 2mm (1.25mm – 3.3 mm);  in‐plane resolution 0.98 ‐1.95 























deoxy‐d‐glucose  (FDG), was  injected  intravenously,  followed  by  physiologic  saline  (10 





















































aid decision making  [1]. The role of medical  imaging however,  is swiftly evolving  from 
primarily a diagnostic tool to also include a more central role in the context of personal‐
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Phantom studies   
Inves�ga�ng inter-scanner and inter-vendor variability of features is important in radi-
omics [23]. In cases where radiomics studies rely on data from mul�ple scanners, neglect-
ing this variability can jeopardize the analysis of studies — that is, the proposed radiomics 
predic�on model might not perform adequately on external datasets if the new data are 
acquired on diﬀerent scanners. As data from pa�ents scanned on mul�ple devices is 
scarce and subject to uncertain�es, including organ mo�on, diﬀerent imaging protocols, 
etc., phantom studies are a suitable means to gauge these uncertain�es and iden�fy fea-
tures that are vendor dependent. In essence, phantom studies offer a risk mi�ga�on 
strategy to help navigate from the current clinical imaging scenario to the desired op�mal 
imaging scenario.  
Imaging at multiple time points 
Addi�onal sources of variability in radiomics features are organ mo�on or expansion or 
shrinkage. Radiomics features that are strongly dependent on these factors can have lim-
ited applicability. To account for these sources of variability, available test-retest data 
Figure 1 – Flowchart depic�ng the workﬂow of radiomics and the applica�on of the RQS. The workﬂow consists
of necessary steps in a radiomics analysis. The RQS both rewards and penalizes the methodology and analyses
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indispensable component of a complete radiomic analysis. Models must be internally val-
idated and should be externally validated. 
Feature selection  
Depending on the number of ﬁlters, feature categories, and other adjustable parameters, 
the possible number of radiomics features that can be extracted from images is virtually 
unlimited. Including all possible features in a model will inevitably result in overﬁ�ng, 
which jeopardizes model performance in unseen pa�ents. To avoid overﬁ�ng, features 
that lack robustness against sources of variability should be eliminated and archetypal 
features selected via dimensionality reduc�on techniques (for example, principal compo-
nent analysis or clustering). For example, a feature that is archetypal for the predic�on 
of overall survival in pa�ents with lung cancer for a given dataset (imaged and segmented 
in a certain way) could be redundant for the predic�on of pneumoni�s in lung cancer for 




Figure 2 – Radiomics in cardiology: the current gold standard for quan�ﬁca�on of coronary calciﬁca�ons visible
on CT is the ‘Agatston’ method (based upon intensity and volume). Radiomic features may improve quan�ﬁca-
�on, diﬀeren�a�on between calciﬁed and non-calciﬁed plaque, and thus the predic�on of Major Adverse Car-
diac Events (MACE). 
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analysis using the same technique and the same data/pa�ents, ensuring that the analysis 
was conducted without error. Replica�on means independent veriﬁca�on of the results 
by independent researchers repea�ng the analysis using the same technique and diﬀer-
ent (but appropriate) data/pa�ents, leading to a stronger aﬃrma�on of the ﬁndings [36-
39]. Radiomics studies involve mul�ple complex sub-processes (such as data selec�on, 
image acquisi�on, feature extrac�on, modelling), each shaped by a wide range of deci-
sions, non-standardized terminology, parametriza�ons, and so�ware. Reproducibility 
and replicability in radiomics is impossible if researchers do not disclose these intricacies. 
The amount of necessary informa�on far exceeds the limits of a tradi�onal manuscript. 
We propose that future radiomics publica�ons should provide the following as supple-
mentary material: imaging protocols, the analyzed scans, segmenta�ons of VOIs, detailed 
accounts of how features are extracted including the formulae, and the modelling meth-
odology (ideally, the code). This level of me�culous detail is required in order to facilitate 
reproduc�on and replica�on. Furthermore, mul�ple radiomics so�ware packages are 
available and are subject to updates or version-control. We recognize that publishing pa-
�ent data might not be possible in all circumstances. As a minimal means of comparison 
and to alleviate this lack of transparency, we propose that researchers publish numerical 
values of their inves�gated features computed on the digital phantom described in the 
supplementary material of this manuscript (available online [40]).   
 To compare diﬀerent so�ware implementa�ons for radiomic feature extrac�on algo-
rithms, we provide CT data of the primary tumour region and the corresponding tumour 
contours of four lung cancer cases, to serve as ‘real life’ digital phantoms (Figure 3). (See 
supplementary material for a detailed descrip�on of the digital phantom image data). 
 
Figure 3 – Radiomics digital phantom data: (a) Representa�ve image of a digital phantom CT image, with the












has advanced  the  field of  radiomics by specifically  identifying an exigent unmet need. 











































sion  signatures, each comprised of dozens  to hundreds of genes,  can  significantly  im‐
prove diagnosis, prognosis, and prediction of treatment response [47‐52]. Seminal radi‐
ogenomic investigations showed the link between radiomic features and gene‐expression 






































































































for the workﬂow of radiomics ought to be independent of vendors and upgrades to hard-
ware and/or so�ware. Radiomic studies should quan�fy reproducibility owing to the ben-
eﬁcial ethical, economic and logis�cal eﬀects (such as informing power calcula�ons and 
required samples sizes, trial dura�on and trial cost). Op�mal reproducibility and stability 
enables mul�centre studies to maximize the likelihood of a validated radiomic signature 
being designated ﬁt-for-purpose in rou�ne clinical use. Prospec�ve studies rela�ng radi-
omics to clinical outcomes in appropriate pa�ent popula�ons and suﬃciently powered 
are pivotal. Numerous studies are underpowered for sensi�vity and speciﬁcity; however, 
study popula�ons should not be skewed by selec�ng only those pa�ents who are more 
capable of adhering to complex imaging protocols than the general popula�on. All ﬁnd-
ings should be published, including true-nega�ves, false-nega�ves and false-posi�ves, 
and the perceived adversity to nega�ve results tempered because substan�al bias risks 
distor�ng the radiomics landscape. 
Economic elements of radiomics investigation 
Mul�centre, collabora�ve and federated eﬀorts are required to share, store, and curate 
data. Data-sharing enables highly powered prospec�ve studies and accelerates the de-
velopment and valida�on of radiomic signatures derived from new and exis�ng data. Net-
worked centres can quickly recruit suﬃcient pa�ent numbers to drive discovery and in-
nova�on. Outcome studies should include health economic considera�ons. Moreover, 
cost-per-quality-adjusted-life-year comparisons should be conducted with and without 
radiomics to more accurately determine the economic poten�al [101]. 
 
 
Figure 4 – Radiogenomics analysis may reveal the rela�onship between imaging phenotypes and gene expres-
sion pa�erns which include expressions of individual genes as well as measures that summarize expressions of
speciﬁc gene subsets. 
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quality  of  the  knowledge  correlates  with  the  number  of  patients  on  whom  that 






that knowledge is gathered as swi�ly and perpetually as possible, while the veracity of 
data is cri�cal to the amount of conﬁdence that can be ascribed to the knowledge gained. 
Data sharing  
Procuring data of suﬃcient quality with regard to the 4Vs is central to RLHC. There is a 
pressing need in both the research and clinical communi�es to embrace knowledge and 
data-sharing technology [106], which transcends ins�tu�onal and na�onal boundaries 
[107]. The following established obstacles to data sharing [108] are apparent in the med-
ical domain: human resources or insuﬃcient �me; cultural and language diﬃcul�es, data 
recording methods; the poli�cal and academic value of data; hazards to reputa�on; legal 
and privacy considera�ons, to name a few. These are all significant issues to address and 
are not easy to overcome. 
 
 
Figure 5 – Schema�c overview of a clinical decision support system graphical user interface illustra�ng the
concept of Δ-radiomics, i.e., a clinician user requests the radiomic analysis of a pa�ent based upon combined
longitudinal PET/CT images enabling poten�ally: improved diagnosis, early response predic�on, improved clin-
ical decision making, and consequently a be�er prognosis. 
Pretreatment Week 1 Week 2 Week 3











































Our vision for radiomics is expansive and bold. In the reasonably near future, we envision 
that CDSS that apply knowledge leveraged from radiomic features mined from global 
RLHC networks populated by (standard-of-care) imaging will enable increased personali-
za�on and precision within medicine. For this vision to be actualized within the rou�ne 
clinical se�ng, clinicians and medical physicists must be incen�vized to par�cipate in the 
process; standardiza�on is crucial to this endeavor, principally in high-quality data acqui-
si�on (clinical, treatment, imaging, gene�c, etc.). Standardiza�on obliges coherent clini-
cal guidelines with agreed standards for image acquisi�on and analysis, as well as data-
sharing techniques that exploit matching ontologies. Con�nuous re-evalua�on and 
demonstra�ng the clinical u�lity of a CDSS is as signiﬁcant as standardizing the develop-
ment and valida�on of the design of clinical trials. These crucial steps are the founda�ons 
of a successful CDSS. Simultaneous and synergis�c advances in RLHC and radiomics will 
empower the next major breakthroughs in personaliza�on and precision medicine. 
 
Figure 6 – Schema�c diagram of the CAT system. Mul�ple centers are linked via their Learning Connectors. The
connector is the interface where machine learning algorithms, which are sent from the learning coordinator,
learn models from local data but privacy-sensi�ve informa�on never leaves the ins�tute. Partner sites exist in
the Netherlands, Germany, Belgium, Italy, Denmark, Australia, China, India, Ireland, UK, and the USA. The sys-
tem is built from a combina�on of open source informa�on communica�on technologies and can deliver data
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Figure 7 – Overview of the methodological processes for RLHC and how the radiomics workﬂow ﬁts into the
development of a CDSS: Data selec�on, discovery, collec�on and prepara�on, model(s) development/valida�on
and implementa�on, assessment of clinical u�lity and ul�mately reﬁnement through con�nuous repe��on of
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SUPPLEMENTARY MATERIAL 
Digital phantom data 
Description of the digital phantom image data 
To compare diﬀerent so�ware implementa�ons for radiomic feature extrac�on algo-
rithms, we provide CT data of the primary tumor region (i.e. a 5 cm margin around the 
tumor volume) and the corresponding tumor contours of 4 lung cancer cases, to serve as 
“real life” digital phantoms. The images have an in plane pixel spacing of 0.977 mm and 
a slice thickness of 3 mm. The data is provided both in original and pre-processed form. 
All image and contour data is provided in DICOM format and is publicly available (DOI: 
10.17195/candat.2016.08.1). The data was generated in Matlab R2014a (The Math-
works, Na�ck, MA) using an adapted version of CERR [1]. The DICOM RTSTRUCTs, con-
taining the contour coordinates, may be used to compare diﬀerent implementa�ons to 




To be able to correctly compare between diﬀerent implementa�ons of feature extrac�on 
algorithms, resul�ng feature values should not be aﬀected by diﬀerences in segmenta-
�on and intensity discre�za�on, which are part of image pre-processing. To ensure that 
the same region of interest (ROI) is used for feature calcula�ons–elimina�ng dependency 
of feature values on segmenta�on–the delinea�on of the primary tumor (GTV) has been 
converted to a 3D binary ([0,1]) mask image ( ; Figure 1a) and applied to the original 
image. 
 We provide two pre-processed images per digital phantom:  (Figure 1b), the original 
image with an oﬀset of +1000 Hounsﬁeld Units (HU), elimina�ng nega�ve values (air = 0 
HU), and  (Figure 1c) a gray value image discre�zed into equally spaced bins, with a bin 
Figure 1 – (a) The 3D binary mask . (b) The pre-processed image with an oﬀset of + 1000 HU ( ). (c) The pre-






  ܫ஻ሺݔሻ ൌ ඄ܫሺݔሻܤ ඈ െ min ൬඄
ܫሺݔሻ
ܤ ඈ൰ ൅ 1  (1) 
Where  term ሾminሺڿܫሺݔሻ ܤ⁄ ۀሻ ൅ 1ሿ ensures  that  the bin count starts at 1. Since differ‐
ences in intensity discretization affect the resulting feature values [2], the gray values of 
the pre‐processed images should therefore be used as‐is. Voxels outside the ROI, which 




























































To  facilitate  further  development  and  acceptance  of  radiomics,  this  thesis  aimed  to 
provide  deeper  understanding  of  several  fundamental  technical  and  methodological 
aspects,  in particular  related  to  interoperability  (Chapter 3‐5).  This  thesis  furthermore 
investigated potential clinical applications of radiomics with a number of proof of concept 
studies focusing on lung and head and neck cancer (Chapters 6‐8). 
  Radiomics  is  a  relatively  young,  yet  fast  growing  research  field, which  holds  great 
promise in precision medicine. Radiomics is extensively discussed in recent literature [1‐
10]. However, the work presented in Chapter 9 aimed to go one step futher, by not only 
providing  an  extensive  review  and  discussion  of  radiomics  with  its  challenges  and 
opportunities,  but  also  providing  a  digital  phantom  and  a  radiomics  quality  score  to 









more  robust  against  inter‐observer  variability.  In  Chapter  6,  a  similar  feature  ranking 
approach  was  applied  to  select  reliable  features  derived  from  CT  images  for  the 
development of a prognostic radiomic signature. Even though such stability analyses are 





acquisition  and  reconstruction  settings,  disease  site,  test‐retest  scan  time  interval,  or 
respiratory motion [12] which should ideally be independently tested for their influence. 
It  is  therefore  advisable  to  perform  test–retest  analyses  that  are  study  specific  and 
controlled for these factors. Phantom studies, as discussed in Chapter 9, can serve as an 
important  and  useful  tool  to  isolate  and  independently  assess  the  effect  of  different 
possible sources of variability [13, 14].  
  Nonetheless,  test‐retest  data  is  not  always  available.  In  another  recent  study, we 
therefore proposed to use different phases of respiratory correlated 4DCT scans as an 
alternative for test‐retest data, since 4DCT is routinely acquired for treatment planning 
purposes  [15]  (not  part  of  this  thesis).  A  strong  agreement  between  feature  stability 






meaningless  and unreliable  features,  since  the  same association with  the outcome of 
interest is unlikely to be consistently found for an unstable/unreliable feature in different 
data  partitions  (e.g.  when  using  repeated  cross‐validation  for model  selection),  or  in 
independent validation datasets. Even though such a data driven approach may provide 
satisfactory  results,  it  is  nevertheless  favorable  to  include  appropriate  data  to  assess 
feature stability whenever available. 
  In Chapter 4, two conceptually different methods for  image  intensity discretization 
were  compared  for  calculating  several  widely  used  textural  features.  Here,  it  was 
concluded  that  that  the  manner  of  image  intensity  discretization  has  an  effect  on 
resulting  textural  features  and,  more  importantly,  has  a  crucial  impact  on  their 
interpretation. The latter suggested that intensity discretization using different bin widths 
might  provide  complementary  information.  A more  general  approach  is  therefore  to 
consider  features calculated with different bin widths  (or number of bins) as different 
features  altogether,  meaning  that  the  intensity  discretization  scheme  is  part  of  the 
feature definitions [14]. In Chapter 8, this was exploited by calculating features for two 
different bin widths. 







  Chapter 5 presented a  study of  the  interoperability of  two  independent  radiomics 
software  implementations,  namely  the  software  developed  as  part  of  this  thesis 
(addendum Software development) and in‐house developed software from the University 
Hospital Zürich. This comparison was performed in the context of the development of a 
prognostic  radiomic model  for  local  tumor control  in head and neck cancer, based on 
post‐radiochemotherapy PET imaging. Both software implementations were each used 
to develop an independent local recurrence model, only considering features which were 
based  on  the  same  definition  and  available  in  both  implementations.  Both  of  these 
models were  found  to be prognostic  for  local  tumor  control  in HNSCC and  contained 













Chapter  5,  the  image  biomarker  standardisation  initiative  (IBSI)  is  an  independent 
international collaboration, which aims to address this challenge by standardization of 
image biomarkers [21]. The IBSI therefore sets out to provide a common nomenclature 
and  definitions  for  image  biomarkers,  benchmarks  for  image  processing  and  feature 
extraction, as well as reporting guidelines. Incorporating the results from this initiative in 









relevance  of  the  presented  findings,  the  radiomic  signature  performed  better  in 
independent cohorts than TNM classification [23], which is routinely used in the clinic for 
treatment  selection.  Furthermore,  radiogenomic  analysis  revealed  that  the  signature, 
which  is  related  to  intra‐tumor  heterogeneity,  correlates  with  underlying  gene‐
expression patterns. 
  Chapter  7  presented  further  validation  of  the  prognostic  value  of  this  radiomic 















  In  Chapter  8,  it  was  investigated  whether  human  papilloma  virus  (HPV)  status  of 
OPSCC patients, determined by p16 immunohistochemistry, can be objectively identified 
by a quantitative radiomic approach. Previous exploratory studies were either based on 
small  data  sets without  validation,  or  single  institution  data  [26,  27].  The multicenter 
study presented in Chapter 8 developed and validated a CT based radiomic signature to 
predict  HPV  status  in  778  patients  from  four  independent  institutions.  Although  not 
intended to replace existing HPV tests, the results of this study provide a proof of concept 
that  radiomics  is able  to derive molecular  information  from standard medical  images. 
Another recent proof of concept study on genotype‐phenotype interactions, furthermore 
illustrates  the  potential  for  developing  noninvasive  radiomic  biomarkers  for  somatic 
mutations in NSCLC patients [28]. 









The majority of  radiomic  studies,  including  the work described  in Chapters 5‐8 of  this 







treatment  planning  CT,  we  were  able  to  show  that  a  number  of  radiomic  features, 


























task  through  a  process  of  optimization,  including  features  with  varying  levels  of 
complexity  [41,  42].  Although  deep  learning  is  a  very  promising  development,  a 
prominent  challenge  is  the  requirement  of  large  amounts  of  data.  Nonetheless,  the 
added value of human defined radiomic features to deep learning should not be ignored 
and may  be more  practical  and  effective  than  substantially  increasing  the  number  of 





the  FAIR  principle,  which  stands  for  Findability,  Accessibility,  Interoperability,  and 
Reusability [47, 48]. Standardization initiatives, such as the IBSI, as well as international 
federated  data  sharing  platforms  employing  ontologies  for  radiomic  data  [17,  22] 
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The workﬂow of radiomics (Figure 1) starts with the acquisi�on of medical images and 
segmenta�ons of structures (i.e. regions of interest), such as the gross tumor volume 
deﬁned for radiotherapy treatment planning purposes. Subsequently, large numbers of 
quan�ta�ve imaging features are extracted from the deﬁned structures. These features 
can then be analyzed for their associa�on with speciﬁc outcomes, in order to develop 
diagnos�c, theragnos�c, prognos�c and predic�ve imaging biomarkers: so-called radio-
mic signatures. 
 Part of the work presented in this thesis consists of the development of so�ware to 
enable the high-throughput extrac�on of radiomic features, as well as validated signa-
tures [1], from medical images to facilitate further research in the ﬁeld of radiomics. This 
chapter brieﬂy describes the developed research so�ware and its func�onality. 
 
FUNCTIONALITY 
The so�ware is designed in Matlab (MathWorks, Na�ck, Massachuse�s, USA) and pro-
vides three main func�onali�es: (1) data management, (2) radiomic workﬂow manage-
ment, and (3) management of results. 
Data 
The so�ware is able to process diﬀerent imaging modali�es, such as CT, PET and MR im-
aging, and associated structure segmenta�ons. DICOM imaging data (CT, PET, or MR) and 
DICOM RTSTRUCT (containing segmenta�on contour data) are imported and converted 
and, once completed, the contents of the data can be (re)viewed. Radiotherapy structure 
sets (RTSTRUCT) usually contain delinea�ons of mul�ple structures for treatment plan-
 
Figure 1 – The workﬂow of radiomics. The ﬁrst step is the acquisi�on of medical images and segmenta�ons of
structures (i.e. regions of interest; ROI). Subsequently, large numbers of radiomic features are extracted from
the deﬁned structures. These features are then analyzed for their associa�on with speciﬁc outcomes to develop
radiomic signatures, based on which reports are generated for clinical decision support. 














































[5], grey‐level size‐zone  (GLSZM)  [6, 7], neighbouring grey‐level dependence  (NGLDM) 
[8],  and  neighbourhood  grey‐tone  difference  (NGTDM)  [9] matrices.  Filtered  features 
(group IV) are features calculated after wavelet decomposition and after application of 
Figure 4 – Results management within the software. Here, the specified radiomic workflow is executed, gener‐
ating  results  for each workflow module and specified structure  for each  included  image data set. Once  the
processing of the workflow is finished, the output, containing all relevant feature and signature data, is exported
in either XLSX or CSV format for further processing or analysis. A green checkbox is shown next to complete and







By applying a  Laplacian of Gaussian  filter,  textural properties  representing  features of 




















































































  The  research  carried  out  at Maastricht  Radiation  Oncology  (MAASTRO)  clinic  and 
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